Bharat Immunologicals & Biologicals Corporation Limited
BIBCOL
CIN – L24232UP1989GOI010542 (A Govt. of India Undertaking)
Regd. Office: Vill. Chola, Bulandshahr(UP)-Pin 203203
Phone (09458096110), Tele Fax -05732 238757
Email – sklalaes@yahoo.co.in Website- www.bibcol.com

No.BIB/CS/SE/UAFR-Q3/2020-21
Date 10.02.2021

To
The Listing Department
Bombay Stock Exchange
Phiroze jeejeebhoy Tower
25, Dalal Street, Mumbai – 400001

Sub: Submission of Unaudited Quarterly Financial Results for the quarter and nine months ended December 2020 as Compliance of LODR 2015

Sir/Madam,

In pursuance of the LODR with Stock Exchange, please find enclosed the Unaudited quarterly financial results for the quarter and nine months ended December 2020 approved by the Board of the Company in its Meeting on 10.02.2021.

Submitted please.

Thanking you,

For **BHARAT IMMUNOLOGICAL AND BIOLOGICAL CORPORATION LIMITED (BIBCOL)**

Sandip Kumar Lal
(General Manager/Company Secretary)

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD. (BIBCOL)

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LIMITED

CIN:- L24232UP1989GOI010542

Part I

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER AND NINE MONTHS ENDED ON 31-12-2020

(INR in Lakh)

S. No	Particulars	3 Months Ended on 31-12-2020	Preceding 3 Months Ended on 30-09-2020	Corresponding 3 Months Ended in the previous year 31-12-2019	Year to Date Figures for Current Period Ended on 31-12-2020	Previous Year Ended as on 31-03-2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**INCOME**					
	a) Income from Operations	2,519.89	2,535.83	2,848.43	6,971.01	6,683.65
	b) Other Income	120.03	13.75	47.08	75.61	118.37

Part II

Selected Information for the Period Ended 31-12-2020

S. No	Particulars	3 Months Ended on 31-12-2020	Preceding 3 Months Ended on 30-09-2020	Corresponding 3 Months Ended in the previous year 31-12-2019	Year to Date Figures for Current Period Ended on 31-12-2020	Previous Year Ended as on 31-03-2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A1	PARTICULARS OF SHAREHOLDING					
	Public shareholding					
	- Number of Shares	17,594,000.00	17,594,000.00	17,594,000.00	17,594,000.00	17,594,000.00
	- Percentage of shareholding (as a% of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of shareholding (as a% of the total share capital of the company)	40.75	40.75	40.75	40.75	40.75
	b) Non - encumbered					
	- Number of Shares	25,586,000.00	25,586,000.00	25,586,000.00	25,586,000.00	25,586,000.00
	- Percentage of shareholding (as a% of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of shareholding (as a% of the total share capital of the company)	59.25	59.25	59.25	59.25	59.25

B	Particulars	3 Months ended (31/12/2020)
	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	-
	Received during the quarter	-
	Disposed of during the quarter	-
	Remaining unresolved at the end of the quarter	-

Segment Reporting for the Period Ended 31-12-2020

(INR in Lakh)

S. No	Particulars	3 Months Ended on 31-12-2020	Preceding 3 Months Ended on 30-09-2020	Corresponding 3 Months Ended in the previous year 31.12.2019	Year to Date Figures for Current Period ended on 31.12.2020	Previous Year Ended as on 31.03.2020
1	SEGMENT REVENUE					
	Oral Polio Vaccine	2,518.16	2,533.57	2,851.91	6,963.73	6,685.82
	Zinc Dispersible Tablets	-	0.03	3.48	0.46	0.23
	BD Sweet Tablets	-	-	-	-	-
	BIBSANT	1.73	2.23	-	7.12	-
	Less: Inter segment revenue	-	-	-	-	-
	Net Sales/ Income from operations	2,519.89	2,535.83	2,848.43	6,971.31	6,686.05
2	SEGMENT RESULTS (Profit Before Tax)					
	Oral Polio Vaccine	-240.73	-855.49	-316.80	-906.12	-1,470.56
	Zinc Dispersible Tablets	-1.50	-2.16	-3.48	-4.74	-9.73
	BD Sweet Tablets	-	-	-	-	-
	BIBSANT	-0.69	-0.88	-	-4.19	-
	Less: Un allocable expenditure net off un allocable income	-	-	-	-	-
	Total Profit before Tax	-242.92	-858.53	-320.28	-915.06	-1,480.33
3	CAPITAL EMPLOYED (Segment Assets less Liabilities)					
	Oral Polio Vaccine	3,774.85	4,373.81	1,474.18	3,774.85	914.05
	Zinc Dispersible Tablets	-230.13	-228.56	-223.54	-230.13	-8.72
	BD Sweet Tablets	0.03	0.03	0.03	0.03	0.03
	BIBSANT	-	-	-	-	-
	Others	-0.38	-0.38	918.67	-0.38	-51.85
	Total Capital employed	3,544.37	4,144.90	1,868.91	3,544.37	853.51

Statement of Assets and Liabilities as at 31st December, 2020

Particulars		As at 31st December, 2020	As at 31st march, 2020
A	**ASSETS**		
1	**Non-current assets**		
	(a) Property, Plant and Equipment	428.76	446.51
	(b) Capital work-in-progress	21.93	21.93
	(c) Financial Assets	980.37	1,363.32
	(d) Other non-current assets	44.84	51.50
	(e) Non Current Tax Assets (Net)	84.38	97.96
	(f) Deferred tax assets (net)	1,657.07	1,399.75
	Total Non-current assets	**3,217.35**	**3,380.97**
2	**Current assets**		
	(a) Inventories	2,340.57	5,171.89
	(b) Financial Assets	0	0
	(i) Investments	0	0
	(ii) Trade receivables	1,941.36	1,761.38
	(ii) Cash and cash equivalents	95.16	98.50
	(iii) Bank balances other than (ii) above	238.98	1,111.34
	(c) Other current assets	1,066.78	1,158.90
	Total Current assets	**5,682.85**	**9,302.01**
	Total Assets	**8,900.20**	**12,682.98**
B	**EQUITY AND LIABILITIES**		
1	**Equity**		
	(a) Equity Share capital	4,318.00	4,318.00
	(b) Other Equity	(2,925.33)	(2,270.62)
	Total Equity	**1,392.67**	**2,047.38**
2	**Non-current liabilities**		
	(a) Deferred Grant	-	-
	(b) Long Term Provisions	579.24	564.85
	Total Non-current liabilities	**579.24**	**564.85**
3	**Current liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	3,893.15	303.84
	(ii) Trade payables	1,585.06	4,353.15
	(iii) Other Financial Liabilities	36.49	38.24
	(b) Deferred Grant	-	-
	© Short Term Provisions	92.33	87.91
	(d) Other Current liabilities	1,321.26	5,287.61
	Total Current liabilities	**6,928.29**	**10,070.75**
	Total Liabilities	**8,900.20**	**12,682.98**

Cash flow statement, Indirect		
Particulars		9 months ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2020
B	Date of end of reporting period	31-12-2020
C	Whether results are audited or unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone
Part I	**Blue color marked fields are non-mandatory.**	
	Statement of cash flows	
	Whether cash flow statement is applicable on company	Yes
	Cash flows from used in operating activities	
	Profit before tax	-911.96
	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	355.310
	Adjustments for decrease (increase) in inventories	2831.320
	Adjustments for decrease (increase) in trade receivables, current	-179.980
	Adjustments for decrease (increase) in trade receivables, non-current	0.000
	Adjustments for decrease (increase) in other current assets	92.120
	Adjustments for decrease (increase) in other non-current assets	20.160
	Adjustments for other financial assets, non-current	382.950
	Adjustments for other financial assets, current	0.000
	Adjustments for other bank balances	0.000
	Adjustments for increase (decrease) in trade payables, current	-2768.090
	Adjustments for increase (decrease) in trade payables, non-current	0.000
	Adjustments for increase (decrease) in other current liabilities	-3966.350
	Adjustments for increase (decrease) in other non-current liabilities	0.000
	Adjustments for depreciation and amortization expense	17.760
	Adjustments for impairment loss reversal of impairment loss recognized in profit or loss	0.000
	Adjustments for provisions, current	4.420
	Adjustments for provisions, non-current	14.390
	Adjustments for other financial liabilities, current	-1.750
	Adjustments for other financial liabilities, non-current	0.000
	Adjustments for unrealized foreign exchange losses gains	0.000
	Adjustments for dividend income	0.000
	Adjustments for interest income	-15.960
	Adjustments for share-based payments	0.000
	Adjustments for fair value losses (gains)	0.000
	Adjustments for undistributed profits of associates	0.000
	Other adjustments for which cash effects are investing or financing cash flow	0.000
	Other adjustments to reconcile profit (loss)	0.000
	Other adjustments for non-cash items	0.000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0.000
	Total adjustments for reconcile profit (loss)	-3213.700
	Net cash flows from (used in) operations	-4125.660

	Dividends received	-
	Interest paid	0.000
	Interest received	0.000
	Income taxes paid (refund)	0.000
	Other inflows (outflows) of cash	-
	Net cash flows from (used in) operating activities	-4125.660
	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0.000
	Cash flows used in obtaining control of subsidiaries or other businesses	0.000
	Other cash receipts from sales of equity or debt instruments of other entities	0.000
	Other cash payments to acquire equity or debt instruments of other entities	0.000
	Other cash receipts from sales of interests in joint ventures	0.000
	Other cash payments to acquire interests in joint ventures	0.000
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0.000
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0.000
	Proceeds from sales of property, plant and equipment	0.000
	Purchase of property, plant and equipment	0.000
	Proceeds from sales of investment property	0.000
	Purchase of investment property	0.000
	Proceeds from sales of intangible assets	0.000
	Purchase of intangible assets	0.000
	Proceeds from sales of intangible assets under development	0.000
	Purchase of intangible assets under development	0.000
	Proceeds from sales of goodwill	0.000
	Purchase of goodwill	0.000
	Proceeds from biological assets other than bearer plants	0.000
	Purchase of biological assets other than bearer plants	0.000
	Proceeds from government grants	0.000
	Proceeds from sales of other long-term assets	0.000
	Purchase of other long-term assets	0.000
	Cash advances and loans made to other parties	0.000
	Cash receipts from repayment of advances and loans made to other parties	0.000
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0.000
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0.000
	Dividends received	0.000
	Interest received	15.960
	Income taxes paid (refund)	0.000
	Other inflows (outflows) of cash	0.000
	Net cash flows from (used in) investing activities	15.960

	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0.000
	Payments from changes in ownership interests in subsidiaries	0.000
	Proceeds from issuing shares	0.000
	Proceeds from issuing other equity instruments	0.000
	Payments to acquire or redeem entity's shares	0.000
	Payments of other equity instruments	0.000
	Proceeds from exercise of stock options	0.000
	Proceeds from issuing debentures notes bonds etc	0.000
	Proceeds from borrowings	3589.310
	Repayments of borrowings	0.000
	Payments of finance lease liabilities	0.000
	Payments of lease liabilities	0.000
	Dividends paid	0.000
	Interest paid	355.310
	Income taxes paid (refund)	0.000
	Other inflows (outflows) of cash	0.000
	Net cash flows from (used in) financing activities	3234.000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	-875.700
	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	
	Net increase (decrease) in cash and cash equivalents	-875.700
	Cash and cash equivalents cash flow statement at beginning of period	1209.840
	Cash and cash equivalents cash flow statement at end of period	334.14

Notes to the Results

1. The above Un-Audited results for the Quarter and nine months ended 31st December, 2020 have been reviewed by the Audit Committee and were taken on record by the Board of Directors in their meeting held on February 10, 2021.
2. Valuation of Closing Stock has been done on the basis of IND AS-2.
3. Depreciation has been charged on the basis of Companies Act 2013
4. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rule 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognised accounting practices and policies to the extent applicable.
5. The format for unaudited quarterly results as prescribed in SEBI's Circular dated November 30, 2015 has been modified to comply with requirements of SEBI's Circular dated July 5, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
6. The statement does include Ind AS compliant results for the preceding quarter and previous year.
7. Segment information as per Ind AS 108 has been given above as Segment Reporting. The Company is currently engaged in production of Oral Polio Vaccine, Zinc Dispersible Tablets and Sweetener.
8. The Ind As compliant corresponding figures in the previous year have been subjected to review / audited. However, the company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.

9. The reconciliation of net profit or loss reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS. For Table, kindly refer Corporate Announcements on www.bseindia.com.

10. Previous year/quarter figures have been regrouped/re-arranged wherever necessary, to make it comparable.

(Chandra Prakash Goyal)
Managing Director

Date :- 10.02.2021